Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

Angela Dispenzieri, Robert A. Kyle, Morie Gertz, Terry M Therneau, Wayne L. Miller, Krishnaswamy Chandrasekaran, Joseph P. McConnell, Mary F. Burritt, Allan S Jaffe

Research output: Contribution to journalArticle

220 Citations (Scopus)

Abstract

Patients with primary systemic amyloidosis that affects the heart have a poor outlook. Cardiac troponins T and I (cTnT, cTnI) are highly specific and sensitive biomarkers of myocardial injury. Values of these troponins provide quantitative information about the disease. We retrospectively assessed 261 patients newly diagnosed as having primary systemic amyloidosis. Median survival for patients with detectable cTnT and cTnI (6 and 8 months, respectively), was worse than that for those with undetectable values (22 and 21 months, respectively). Median and 25th and 75th percentile values for cTnT were 0.024 μg/L, less than 0.01 μg/L, and 0.084 μg/L, and for cTnI were 0.1 μg/L, 0.05 μg/L, and 0.24 μg/L, respectively. After multivariate analysis, cTnT proved a better predictor of survival than cTnI.

Original languageEnglish (US)
Pages (from-to)1787-1789
Number of pages3
JournalLancet
Volume361
Issue number9371
DOIs
StatePublished - May 24 2003

Fingerprint

Troponin
Survival
Serum
Troponin T
Troponin I
Multivariate Analysis
Biomarkers
Wounds and Injuries
Primary amyloidosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. / Dispenzieri, Angela; Kyle, Robert A.; Gertz, Morie; Therneau, Terry M; Miller, Wayne L.; Chandrasekaran, Krishnaswamy; McConnell, Joseph P.; Burritt, Mary F.; Jaffe, Allan S.

In: Lancet, Vol. 361, No. 9371, 24.05.2003, p. 1787-1789.

Research output: Contribution to journalArticle

Dispenzieri, Angela ; Kyle, Robert A. ; Gertz, Morie ; Therneau, Terry M ; Miller, Wayne L. ; Chandrasekaran, Krishnaswamy ; McConnell, Joseph P. ; Burritt, Mary F. ; Jaffe, Allan S. / Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. In: Lancet. 2003 ; Vol. 361, No. 9371. pp. 1787-1789.
@article{2191612bfca64660b9b921e6fae9d96d,
title = "Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins",
abstract = "Patients with primary systemic amyloidosis that affects the heart have a poor outlook. Cardiac troponins T and I (cTnT, cTnI) are highly specific and sensitive biomarkers of myocardial injury. Values of these troponins provide quantitative information about the disease. We retrospectively assessed 261 patients newly diagnosed as having primary systemic amyloidosis. Median survival for patients with detectable cTnT and cTnI (6 and 8 months, respectively), was worse than that for those with undetectable values (22 and 21 months, respectively). Median and 25th and 75th percentile values for cTnT were 0.024 μg/L, less than 0.01 μg/L, and 0.084 μg/L, and for cTnI were 0.1 μg/L, 0.05 μg/L, and 0.24 μg/L, respectively. After multivariate analysis, cTnT proved a better predictor of survival than cTnI.",
author = "Angela Dispenzieri and Kyle, {Robert A.} and Morie Gertz and Therneau, {Terry M} and Miller, {Wayne L.} and Krishnaswamy Chandrasekaran and McConnell, {Joseph P.} and Burritt, {Mary F.} and Jaffe, {Allan S}",
year = "2003",
month = "5",
day = "24",
doi = "10.1016/S0140-6736(03)13396-X",
language = "English (US)",
volume = "361",
pages = "1787--1789",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9371",

}

TY - JOUR

T1 - Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

AU - Dispenzieri, Angela

AU - Kyle, Robert A.

AU - Gertz, Morie

AU - Therneau, Terry M

AU - Miller, Wayne L.

AU - Chandrasekaran, Krishnaswamy

AU - McConnell, Joseph P.

AU - Burritt, Mary F.

AU - Jaffe, Allan S

PY - 2003/5/24

Y1 - 2003/5/24

N2 - Patients with primary systemic amyloidosis that affects the heart have a poor outlook. Cardiac troponins T and I (cTnT, cTnI) are highly specific and sensitive biomarkers of myocardial injury. Values of these troponins provide quantitative information about the disease. We retrospectively assessed 261 patients newly diagnosed as having primary systemic amyloidosis. Median survival for patients with detectable cTnT and cTnI (6 and 8 months, respectively), was worse than that for those with undetectable values (22 and 21 months, respectively). Median and 25th and 75th percentile values for cTnT were 0.024 μg/L, less than 0.01 μg/L, and 0.084 μg/L, and for cTnI were 0.1 μg/L, 0.05 μg/L, and 0.24 μg/L, respectively. After multivariate analysis, cTnT proved a better predictor of survival than cTnI.

AB - Patients with primary systemic amyloidosis that affects the heart have a poor outlook. Cardiac troponins T and I (cTnT, cTnI) are highly specific and sensitive biomarkers of myocardial injury. Values of these troponins provide quantitative information about the disease. We retrospectively assessed 261 patients newly diagnosed as having primary systemic amyloidosis. Median survival for patients with detectable cTnT and cTnI (6 and 8 months, respectively), was worse than that for those with undetectable values (22 and 21 months, respectively). Median and 25th and 75th percentile values for cTnT were 0.024 μg/L, less than 0.01 μg/L, and 0.084 μg/L, and for cTnI were 0.1 μg/L, 0.05 μg/L, and 0.24 μg/L, respectively. After multivariate analysis, cTnT proved a better predictor of survival than cTnI.

UR - http://www.scopus.com/inward/record.url?scp=0038778403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038778403&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(03)13396-X

DO - 10.1016/S0140-6736(03)13396-X

M3 - Article

VL - 361

SP - 1787

EP - 1789

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9371

ER -